By: Benzinga
April 02, 2013 at 16:11 PM EDT
Novavax Offers Top-Line Results from Phase 2 Trial of RSV Vaccine Candidate, Says Safety Will Be Evaluated Over Total Six Months
Novavax, Inc. (Nasdaq: NVAX ) today announced that top-line data from the Phase II dose-ranging clinical trial of its respiratory syncytial virus (RSV) vaccine candidate in women of childbearing age accomplished the trial's protocol-specified objectives and supports progression to the next stage of advanced clinical testing. The trial represents an important step towards
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here